Skip to main content

Aortic Aneurysm

Haemocomplettan® P During Aortic Replacement
NCT00701142 | PHASE 2 | INTERVENTIONAL

The primary purpose is to show that administration of Haemocomplettan® P significantly reduces the amount of blood products needed during aortic surgery.

Trial Information
1 Sites
80 Participants
Recruiting
18 Years to 65 Years

If interested, contact clinicaltrials@cslbehring.com for more information

CSL Behring respects your privacy. For an explanation of how CSL Behring will use the information you are submitting, please view our Privacy Policy

Medical School Hannover (MHH)
Hannover,Germany

Study Eligibility Criteria

Additional Studies

Additional studies can be found at ClinicalTrials.gov